retatrutide phase 2 obesity nejm 2023 jastreboff 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide Dosing Guide: 1-12 mg

10.1186/s12989-022-00460-3 7 AlbaneseA.TangP

Toxicity of excipients and carriers Some excipients or carrier materials used in these formulations, especially surfactants in SMEDDS or certain polymers in nanoparticles, might have inherent toxicity concerns, particularly with long-term use or at high doses

As we look to 2026, the story becomes one of defining firsts: the debut of oral GLP-1s, the first loss of exclusivity for a GLP-1 receptor antagonist, and landmark coverage decisions such as obesity medications entering Medicare formularies for obesity as a standalone indication

I actually really liked hearing this

References: Harwood K, Patricia V, DiMartino-Nardi J